Short bowel syndrome (SBS) is a severe condition marked by malabsorption of nutrients and dependence on intravenous nutrition. In a recent study, researchers from Japan explored how glucagon-like peptide-2 (GLP-2) analog therapy transforms the intestinal environment at the cellular level. Using single-cell analysis and microbiome profiling, they revealed that GLP-2 analog treatment promotes gut remodeling, enhances nutrient absorption, reduces inflammation, and reshapes the microbiome—offering key insights for improving SBS therapy.

Bulimia nervosa is an eating disorder that often goes untreated owing to limited access to specialist care. To address this, researchers tested a guided internet-based cognitive behavioral therapy program for women with bulimia that could be delivered online. They found that online therapy reduced binge eating and purge behaviors and achieved improved remission rates compared to usual care, offering a promising way to make effective treatment more accessible for people with limited clinic access.

Peptidyl-arginine deiminase 2 (PAD2) enzyme converts arginine amino acid residues in histone proteins into citrulline groups and promotes tumor cell proliferation in pancreatic ductal adenocarcinoma, report researchers from Institute of Science Tokyo, Japan. Administration of PAD inhibitors reduced PRUNE1 expression and suppressed tumor cell proliferation in both pancreatic cancer cell lines and mouse models. The study thus lays the foundation for future anticancer therapies targeting PAD2 enzymatic activity.

Using nasal cells from patients, the team succeeded in reproducing, in the laboratory, the initial stages of neural development